GLYC GlycoMimetics Inc. Forward P/S Multiple

GlycoMimetics Inc. (GLYC) - corporate logo

GlycoMimetics, Inc. (GLYC) minimizes capital expenditures by outsourcing production and testing to third-party contractors. This forward P/S trend chart provided by GURU.Markets demonstrates this model, where 1774.30 represents the latest metric reading. However, the firm's stability depends on the success of uproleselan and new investments. Meanwhile, the precision oncology sector remains a defensive asset, independent of global macroeconomic cycles.

GLYC (GlycoMimetics) Price to Expected Revenue Ratio history from 07/04/2022 to 02/14/2025

glycomimetics.com - analytical breakdowns and key metrics (GLYC)

- current price and projected stock value:
Stock Price GlycoMimetics|GLYC - Analyst Target Range
- market capitalization data:
Market Capitalization GlycoMimetics, Inc.|GLYC - Total Enterprise Value
- issuer book value statistics:
Accounting Value per Share GlycoMimetics|GLYC - Total Net Assets|Market Capitalization to Book Value Ratio glycomimetics.com|GLYC - Company Assets
- debt and liquidity data:
Total Debt to Capital GlycoMimetics, Inc.|GLYC - Long-Term Debt to Capital Ratio|Short-Term Debt to Equity Ratio GlycoMimetics|GLYC - Aggregate Debt Obligations|Debt to Book Value GlycoMimetics, Inc.|GLYC - Amount of Long-Term Liabilities|Company Short-Term Debts GlycoMimetics|Quick Ratio glycomimetics.com
- net income and valuation multiples indicators:
GLYC - Company Net Income|Expected Profit GlycoMimetics, Inc.|GLYC - Company Value to Net Income|Forward P/E Multiple GlycoMimetics|GLYC - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization GlycoMimetics, Inc.|GLYC - Profit before deduction of interest, taxes, depreciation and amortization|Net earnings per share for the last 12 months GlycoMimetics|GLYC - Net earnings per one share for the last twelve months|Quarterly EPS earnings growth glycomimetics.com|GLYC - Net earnings per share change in current year|Net earnings per share growth forecast for next year GlycoMimetics, Inc.
- issuer revenue and sales details:
GLYC - Company Revenue|Company Future Sales Volume GlycoMimetics|GLYC - Price to Sales|Forward P/S Multiple GlycoMimetics, Inc.
Summary company analysis:GlycoMimetics Corp (GLYC)
Product sample of GlycoMimetics Inc.

For GlycoMimetics, Inc. (GLYC), this indicator serves as a gauge of market confidence in future cash flows amid geopolitical risks to pharmaceutical supply chains. By analyzing the forward EV/Revenue multiple, an investor assesses the ratio of the company's current value to projected sales, which helps identify overpayment for potential income that may be constrained by barriers in patent protection and the execution of global trials.

Competing companies

Forward P/S Multiple GMAB (Genmab)|Projected Price to Revenue Exelixis Inc|Nuvalent Corp - Forward P/S Multiple|Market Cap to Future Revenue Ratio Kymera Corp|IDYA (IDEAYA Biosciences) - Forward Price-to-Revenue Multiple|ELVN: Price to Expected Revenue Ratio|ORIC (ORIC Pharmaceuticals, Inc.) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Relay Therapeutics Inc RLAY|Forward P/S Multiple NRIX|Tyra Corp - Market Cap to Projected Revenue|Verastem, Inc. - Forward Price-to-Revenue Multiple|Forward Price to Sales GLUE|CGEM: Forward Price-to-Revenue Multiple|Immuneering Corp - Price to Expected Revenue Ratio|CCCC: Forward P/S Multiple|Black Diamond Therapeutics, Inc - Forward Price to Sales|RPTX (Repare Therapeutics) - Forward P/S Multiple|Market Cap to Future Revenue Ratio pmvpharma.com PMVP|Price-to-Projected Revenue Ratio Karyopharm Therapeutics (KPTI)|PPCB (propanc.com) - Forward Price to Sales|Forward P/S Multiple BGMS (Cyclacel Pharmaceuticals)|Forward P/S Multiple Aadi Bioscience Inc AADI|ALRN - Price-to-Projected Revenue Ratio|Future Price to Revenue BPMC|SWTX (SpringWorks Therapeutics, Inc.) - Forward Price-to-Revenue Multiple